Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 02 September 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1672972

This article is part of the Research TopicImmune Plasticity and Cancer: Augmenting Therapeutic Potential of Immunotherapy against Tumor DiseasesView all 8 articles

Correction: Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

This article is a correction to:

  1. Therapeutic Potential of Isochlorogenic Acid A from Taraxacum officinale in Improving Immune Response and Enhancing the Efficacy of PD-1/PD-L1 blockade in Triple-Negative Breast Cancer

    1. Read original article
Tangyi WangTangyi Wang1Jingwei SunJingwei Sun2Li WangLi Wang1Yuxin LinYuxin Lin1Zhijing WuZhijing Wu1Qiangqiang JiaQiangqiang Jia3Shoude ZhangShoude Zhang3Juan An,,Juan An1,4,5Xueman Ma,,Xueman Ma1,4,5Qiong Wu,,Qiong Wu1,4,5Zhanhai Su,,Zhanhai Su1,4,5Haiyan Wang,,*Haiyan Wang1,4,5*
  • 1Department of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, China
  • 2Department of Medical Laboratory, Qinghai Provincial People’s Hospital, Xining, Qinghai, China
  • 3State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, Xining, Qinghai, China
  • 4Research Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, China
  • 5Key Laboratory of the Ministry of High Altitude Medicine, Qinghai University, Xining, Qinghai, China

A Correction on
Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

By Wang T, Sun J, Wang L, Lin Y, Wu Z, Jia Q, Zhang S, An J, Ma X, Wu Q, Su Z and Wang H (2025) Front. Immunol. 16:1529710. doi: 10.3389/fimmu.2025.1529710

There was a mistake in Figure 7F as published. The error was caused by the use of placeholder images during the typesetting process to maintain layout consistency; due to oversight, some placeholders were not replaced with the correct images. The corrected Figure 7F appears below.

Figure 7
A series of scientific data visualizations: (A) A Venn diagram showing shared and unique elements between ICGA-A and CRA datasets. (B) Bar graph illustrating enrichment scores in biological processes, cellular components, and molecular functions. (C) Bubble plot displaying pathway enrichment scores, with color and size indicating significance and count. (D) Line graph depicting Z-scores for ranked pathways, highlighting the PI3K/Akt/mTOR pathway. (E) Heat map of gene expression across groups. (F) Western blot results for proteins FAK, PI3K, AKT, and mTOR in MDA-MB-231 and 4T1 cells treated with DMSO, ICGA-A, and CRA, with bar charts below showing relative protein densities.

Figure 7. ICGA-A and CRA inhibited mRNA and protein expression levels of metabolic-associated proteins and pathways. (A) Venn diagram of DEGs in MDA-MB-231 cells treated with ICGA-A and CRA. (B) The top 10 GO terms in the BP, CC, and MF classifications of overlapping genes with MDA-MB-231. The x-axis represents the enriched terms, and the y-axis represents the enrichment score. (C) Top 20 KEGG pathways. KEGG pathway enrichment for the overlapping genes with MDA-MB-231. The x-axis represents the gene ratio (p < 0.05), and the y-axis represents the enriched terms. (D) The ranking of ICGA-A scored by HTS2 in a library of over 20,000 compounds. (E) Heatmap of the intersecting genes between RNA-seq and network pharmacology targets. (F) ICGA-A and CRA decreased the phosphorylation levels of FAK, PI3K, AKT, and mTOR. *p < 0.05, **p < 0.01, ***p < 0.001 vs. DMSO.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: immune checkpoint blockade, Taraxacum officinale, PD-1/PD-L1 inhibitor 2, tumor microenvironments, triple-negative breast cancer

Citation: Wang T, Sun J, Wang L, Lin Y, Wu Z, Jia Q, Zhang S, An J, Ma X, Wu Q, Su Z and Wang H (2025) Correction: Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer. Front. Immunol. 16:1672972. doi: 10.3389/fimmu.2025.1672972

Received: 25 July 2025; Accepted: 27 August 2025;
Published: 02 September 2025.

Edited and reviewed by:

Hridayesh Prakash, Amity University, India

Copyright © 2025 Wang, Sun, Wang, Lin, Wu, Jia, Zhang, An, Ma, Wu, Su and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Haiyan Wang, d2FuZ2hhaXlhbkBxaHUuZWR1LmNu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.